These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 12244602)

  • 1. Recombinant human erythropoietin in end-stage renal disease.
    Bihl G
    S Afr Med J; 2002 Aug; 92(8):565. PubMed ID: 12244602
    [No Abstract]   [Full Text] [Related]  

  • 2. Quality of life in end-stage renal disease patients during recombinant human erythropoietin therapy. The Canadian Erythropoietin Study Group.
    Keown PA
    Contrib Nephrol; 1991; 88():81-6; discussion 87-9. PubMed ID: 2040199
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost of treating predialysis patients with recombinant human erythropoietin.
    Durand-Zaleski I; Goldfarb B; Blum-Boisgard C; Drüeke T; Kreis H
    Nephrol Dial Transplant; 1993; 8(4):311-4. PubMed ID: 8390004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epoetin: a pharmacoeconomic review of its use in chronic renal failure and its effects on quality of life.
    Whittington R; Barradell LB; Benfield P
    Pharmacoeconomics; 1993 Jan; 3(1):45-82. PubMed ID: 10146987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefits and costs of recombinant human erythropoietin for end-stage renal failure: a review. Benefits and costs of erythropoietin.
    McNamee P; van Doorslaer E; Segaar R
    Int J Technol Assess Health Care; 1993; 9(4):490-504. PubMed ID: 8288425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of the first year of Medicare coverage of erythropoietin.
    Griffiths RI; Powe NR; Greer J; de Lissovoy G; Anderson GF; Whelton PK; Watson AJ; Eggers PW
    Health Care Financ Rev; 1994; 15(3):83-102. PubMed ID: 10137799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO?
    Besarab A; McCrea JB
    ASAIO J; 1993; 39(1):11-8. PubMed ID: 8439674
    [No Abstract]   [Full Text] [Related]  

  • 8. Once again, ESAs are in the eye of the storm.
    Neumann ME
    Nephrol News Issues; 2013 Jan; 27(1):10. PubMed ID: 23431575
    [No Abstract]   [Full Text] [Related]  

  • 9. EPO's cost stirs questions about rationing renal care.
    Bankhead CD
    Med World News; 1988 Dec; 29(23):48. PubMed ID: 10303023
    [No Abstract]   [Full Text] [Related]  

  • 10. Recombinant human erythropoietin therapy in end stage renal failure.
    Watson AJ; Spivak JL
    J Clin Pharmacol; 1988 Dec; 28(12):1086-8. PubMed ID: 3072351
    [No Abstract]   [Full Text] [Related]  

  • 11. Historical clinical and economic consequences of anemia management in patients with end-stage renal disease on dialysis using erythropoietin stimulating agents versus routine blood transfusions: a retrospective cost-effectiveness analysis.
    Naci H; de Lissovoy G; Hollenbeak C; Custer B; Hofmann A; McClellan W; Gitlin M
    J Med Econ; 2012; 15(2):293-304. PubMed ID: 22115328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of life: subjective and objective improvements with recombinant human erythropoietin therapy.
    Lundin AP
    Semin Nephrol; 1989 Mar; 9(1 Suppl 1):22-9. PubMed ID: 2648517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythropoietin in chronic renal failure.
    Valderrábano F
    Kidney Int; 1996 Oct; 50(4):1373-91. PubMed ID: 8887302
    [No Abstract]   [Full Text] [Related]  

  • 14. Induction of fetal hemoglobin by recombinant human erythropoietin in patients with end-stage renal disease.
    Salvati F
    Nephron; 1993; 65(2):313. PubMed ID: 7504213
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical application of recombinant erythropoietin in predialysis renal failure.
    Briggs WA; Gimenez LF
    Hematol Oncol Clin North Am; 1994 Oct; 8(5):927-32. PubMed ID: 7852215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunological effects of recombinant human erythropoietin on end-stage renal disease pediatric and adult patients.
    Salvati F; Liani M; La Torre M; Golato M; Di Sciascio N; Pietrzyk J; Dyras P
    Nephron; 1994; 68(4):510-1. PubMed ID: 7870240
    [No Abstract]   [Full Text] [Related]  

  • 17. Recombinant human erythropoietin and the quality of life of end-stage renal disease patients: a comparative analysis.
    Evans RW
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):62-70. PubMed ID: 1928082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival benefit of recombinant human erythropoietin administration prior to onset of end-stage renal disease: variations across surrogates for quality of care and time.
    Lu WX; Jones-Burton C; Zhan M; Salzberg DJ; Moore J; Fink JC
    Nephron Clin Pract; 2005; 101(2):c79-86. PubMed ID: 15976508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cost minimisation analysis for darbepoetin alpha vs. epoetin alpha in chronic kidney disease patients on haemodialysis].
    Cuesta Grueso C; Poveda Andrés JL; Garcia Pellicer J; Romá Sánchez E
    Farm Hosp; 2010; 34(2):68-75. PubMed ID: 20206567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early adoption of cyclosporine and recombinant human erythropoietin: clinical, economic, and policy issues with emergence of high-cost drugs.
    Powe NR; Eggers PW; Johnson CB
    Am J Kidney Dis; 1994 Jul; 24(1):33-41. PubMed ID: 8023822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.